The BD CTGCTV2 assay is a 3-in-1 FDA-cleared test designed to detect the 3 most prevalent non-viral sexually transmitted infections simultaneously and separately.1-5

BD CTGCTV2 provides reliable results with high sensitivity and specificity to support informed clinical decision-making.2-5

Includes dual gene targets for GC, which maximizes the assay specificity: both GC gene targets are required for a positive GC result.2-4

Utilizes the highly sensitive CDC-recommended
diagnostic technology
, NAAT for CT detection.2-5

Goes one step further in testing for STIs by diagnosing
in addition to GC and CT, using NAAT.2-4

BD CTGCTV2 assay: Flexibility in STI testing

Learn more

CDC, Centers for Disease Control and Prevention; CT, Chlamydia trachomatis; FDA, Food and Drug Administration; GC, Neisseria gonorrhoeae; NAAT, nucleic acid amplification test; STI, sexually transmitted infection; TV, Trichomonas vaginalis.

1. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC. 2021. Accessed 29 Apr 2022.
2. BD CTGCTV2 for BD MAX™ System Package Insert [P0237].
3. Van Der Pol B et al. Sex Transm Dis. 2021;48(2):134–40.
4. Workowski KA et al. MMWR Recomm Rep. 2021;70(4):1–187.
5. Chlamydia – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022.